Phase I studies with thiocarzolamide (NSC-45409).
D000328:Adult; D000368:Aged; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D004285:Dogs; D006801:Humans; D051379:Mice; D008875:Middle Aged; D051381:Rats
D000970:Antineoplastic Agents